Abbott India reports 11% revenue growth in Q2

ABBOTINDIA Limited (NSE: ABBOTINDIA) reported Q2 FY27 revenue of ₹1,951.01 crore, up 11% year on year. Net profit increased 9.2% to ₹453.45 crore. Important business indicators: - Domestic pharmaceutical demand - Growth in established brands - Product launches and portfolio mix - Marketing and distribution expenses - Operating margins My analysis: Revenue and profit growth are relatively close, which suggests that profitability has not expanded at the same pace as some faster-growing pharmaceutical companies. The important question is whether new launches and established brands can improve growth without requiring a disproportionate increase in marketing costs. What I am watching next: Product-wise growth, margins and new launches. My stance: A steady business performance, but valuation should be assessed against its growth rate. Learning outcome: Comparing profit growth with revenue growth helps investors judge whether a pharmaceutical company is maintaining its profitability while expanding sales. Disclosure: This note represents my independent research assessment. I do not hold this stock. This is for informational purposes and should not be considered a recommendation to buy or sell.